ArticleNAM journal2026
On the relevance of genomic approaches to hazard assessment of functionalized nanomaterials in the NAM framework.
Article in NAM journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New approach methodologies (NAMs) are changing the ways by which alternative toxicology, in vitro mainly, is approaching the evaluation of hazard of novel materials or compounds. Engineered nanoparticles (NPs) are a typical class of compounds where NAMs found an important area of application. The number of novel NPs and NPs-based products are increasing at a pace that classical in vivo toxicology has difficult to keep. NAMs on the other hand are faster and may provide more human relevant outcomes. According to the Safe and Sustainable by design (SSbD) framework, we report here the comparison of silver NPs (AgNPs) with different functionalization (naked, with curcumin or with hydroxyethyl cellulose). A lung in vitro model (A549 cells with THP-1-derived macrophages) is exposed with a NAM at the air-liquid interface (ALI). The outcomes are explored with a genomic approach followed by RT-PCR. The results show the relevance of combining two de facto NAM to obtain data relevant to human expected exposure and to mine the plethora of hazard information in vitro model can provide. The combination of these approaches should be considered as a reference approach also to pave the road for regulatory acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.